<html><body><h2>Case: 2345853</h2><h3> CDS Time: 1979-10-12</h3>
<patient name=2345853>
79.0 year old Asian_or_Pacific-Islander_Non-Hispanic Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">79</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">89</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">51</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Chloride</td><td width="200">97.0</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">39</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">54</td><td width="200">1979-10-12</td></tr>
<tr><td width="200">B 12</td><td width="200">158.0</td><td width="200">1978-11-2</td></tr>
<tr><td width="200">Weight</td><td width="200">168</td><td width="200">1979-10-12</td></tr>
<tr><td width="200">HbA1C</td><td width="200">8</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">343</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Urine_ALB/CREAT_RATIO_spot</td><td width="200">11</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Urine_Alb/creat_Ratio_24h</td><td width="200">11</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">142</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">SGOT</td><td width="200">24</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">145</td><td width="200">1979-10-12</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Height</td><td width="200">60</td><td width="200">1979-8-9</td></tr>
<tr><td width="200">Potassium</td><td width="200">4</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">142</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">BUN</td><td width="200">22</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">HCT</td><td width="200">35</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">HGB</td><td width="200">12</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Sodium</td><td width="200">137</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.3</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">UrineAlbumin_24H</td><td width="200">4</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">8</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">UrineAlbumin_SPOT</td><td width="200">4</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Pulse</td><td width="200">60</td><td width="200">1979-10-12</td></tr>
<tr><td width="200">PLT</td><td width="200">230</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">WBC</td><td width="200">8</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">eGFR</td><td width="200">57</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1979-10-12</td></tr>
<tr><td width="200">SGPT</td><td width="200">36</td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Tobacco_Use</td><td width="200"></td><td width="200">1978-9-9</td></tr>
<tr><td width="200">smoking</td><td width="200"></td><td width="200">1978-9-9</td></tr>
<tr><td width="200">tobacco use</td><td width="200"></td><td width="200">1978-9-9</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1979-4-23</td></tr>
<tr><td width="200">Diabetes with renal manifestations</td><td width="200"></td><td width="200">1978-11-23</td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
<tr><td width="200">Secondary_Hypertension</td><td width="200"></td><td width="200">1979-9-8</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1979-10-12</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1979-10-12</td></tr>
<tr><td width="200">Hyperlipidemia</td><td width="200"></td><td width="200">1979-10-12</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1979-10-12</td></tr>
<tr><td width="200">onychomycosis</td><td width="200"></td><td width="200">1979-8-11</td></tr>
<tr><td width="200">Race</td><td width="200">Asian_or_Pacific-Islander_Non-Hispanic</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> aspirin(325.0) losartan(100.0) metformin(2000.0) terazosin(1.0) valsartan(325.0) nitrate(60.0) hydrochlorothiazide(25.0) timolol(2.0) Insulin(15.0) glipizide(20.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[Treatment_Systolic_BP(145/null) && Treatment_Diastolic_BP(54/null)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of cononary artery disease]()</td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension K >=3.5</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[presence of isolated systolic hypertension && Potassium(3.9/1979-9-8)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(39.0/1979-9-8)]()</td></tr>
<tr><td width="200">ISH on HCTZ and BP not controlled</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[presence of isolated systolic hypertension && presence of HCTZ && BP not adequately controlled based on most recent BPTreatment_Systolic_BP(145/null)]()</td></tr>
<tr><td width="200">DM and BP not controlled</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of DM && BP not adequately controlled based on most recent BPTreatment_Systolic_BP(145/null)]()</td></tr>
<tr><td width="200">DM BP not controlled  >=1 drug</td>
<td width="200"></td>
<td width="200"> Diabetes[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(145/null) && presence of diabetes mellitus && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Age(79.0/1970-1-1) && Sex(Male)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(57.0/1979-9-8)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(57.0/1979-9-8)]()</td></tr>
<tr><td width="200">Active prescription for thiazide</td>
<td width="200"></td>
<td width="200"> active prescription for thiazide[presence of thiazide diuretics]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(79.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1979-04-23</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1979-10-12</td>
<td width="200"> Hypertension()</td></tr>
<tr><td width="200">Secondary_Hypertension</td>
<td width="200">1979-09-08</td>
<td width="200"> Secondary_Hypertension()</td></tr>
<tr><td width="200">Psychiatric_Diseases</td>
<td width="200">1978-09-09</td>
<td width="200"> Tobacco_Use()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1979-10-12</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1979-10-12</td>
<td width="200"> DM-Type2()</td></tr>
<tr> <td width="200"></td>
<td width="200">1978-11-23</td>
<td width="200"> Diabetes with renal manifestations()</td></tr>
<tr><td width="200">CCS-1.2</td>
<td width="200">1979-08-11</td>
<td width="200"> onychomycosis()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1979-10-12</td>
<td width="200"> Hyperlipidemia()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200">1978-09-09</td>
<td width="200"> tobacco use()
<tr> <td width="200"></td>
<td width="200">1978-09-09</td>
<td width="200"> smoking()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
<p><b>Allergies and Adverse Reactions:</b> <ul>
<li>Substance: aspirin Reaction: 
<li>Substance: aspirin Reaction: 
 </ul>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Systolic_BP(145/null))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(51.0/1979-9-8))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>Hypertension control <font color=FF0000>preferred</font></b>(rule in criterion<i> BP not under control</i> evaluate to <b> true</b> because <i>BP not under controlTreatment_Systolic_BP(145/null)</i>)])
In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>Ace_Inhibitor(Captopril, Lisinopril, Enalapril)<ul><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>rec add ace: dose adjustent based on kidney functio(Refer to specific ACE Inhibitor dose adjustments based on kidney function.)<li>monitoring renal function and K(Need to find content)<li>preference: preferred</ul><li>ARB<ul><li>Already being used<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>preference: ruled out</ul></ul></body></html>